Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
The Pediatric Infectious Disease Journal|June 4, 2005
Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in childrenAlejandro Hoberman, Ron Dagan, Eugene Leibovitz, et al.
Open Forum Infectious Diseases|May 13, 2024
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO StudyMounir Ait-Khaled, James Oyee, Adrian Yit Reen Ooi, et al.
Plos One|October 23, 2013
"Wrong, but useful": negotiating uncertainty in infectious disease modellingRobert M Christley, Maggie Mort, Brian Wynne, et al.
Viruses|March 28, 2024
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 StudiesMark Underwood, Rimgaile Urbaityte, Ruolan Wang, et al.
European Journal of Clinical Pharmacology|October 8, 2013
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairmentStephen Weller, Julie Borland, Shuguang Chen, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING StudyMark Underwood, Joe Horton, Keith Nangle, et al.
HIV Research & Clinical Practice|June 28, 2021
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trialsFrank Spinelli, Manyu Prakash, Jill Slater, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2018
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 InfectionRashmi Mehta, Allen Wolstenholme, Kristin Di Lullo, et al.
Antimicrobial Agents and Chemotherapy|February 16, 2023
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"Mark Underwood, Joe Horton, Keith Nangle, et al.
BMC Infectious Diseases|July 25, 2016
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjectsLisa L Ross, Ivy H Song, Niki Arya, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
The Pediatric Infectious Disease Journal|June 4, 2005
Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in childrenAlejandro Hoberman, Ron Dagan, Eugene Leibovitz, et al.
Open Forum Infectious Diseases|May 13, 2024
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO StudyMounir Ait-Khaled, James Oyee, Adrian Yit Reen Ooi, et al.
Plos One|October 23, 2013
"Wrong, but useful": negotiating uncertainty in infectious disease modellingRobert M Christley, Maggie Mort, Brian Wynne, et al.
Viruses|March 28, 2024
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 StudiesMark Underwood, Rimgaile Urbaityte, Ruolan Wang, et al.
European Journal of Clinical Pharmacology|October 8, 2013
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairmentStephen Weller, Julie Borland, Shuguang Chen, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING StudyMark Underwood, Joe Horton, Keith Nangle, et al.
HIV Research & Clinical Practice|June 28, 2021
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trialsFrank Spinelli, Manyu Prakash, Jill Slater, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2018
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 InfectionRashmi Mehta, Allen Wolstenholme, Kristin Di Lullo, et al.
Antimicrobial Agents and Chemotherapy|February 16, 2023
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"Mark Underwood, Joe Horton, Keith Nangle, et al.
BMC Infectious Diseases|July 25, 2016
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjectsLisa L Ross, Ivy H Song, Niki Arya, et al.
Pageof 8